Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Mesothelioma
Trial Status:  Active
Results 1-25 of 101 for your search:
Start Over
Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Advanced Lung and Non-colorectal Gastrointestinal Malignancies
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-434, NCT01401907
PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08_DOG07_93, ISRCTN04240319, PB-PG-1010-23232, NCT01604005
Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis
Phase: Phase III
Type: Supportive care
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2013-0308, NCI-2014-00917, NCT01952847
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Phase: Phase III
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A221303, U10CA037447, UG1CA189823, NCI-2014-01943, NCT02349412
Short Neoadjuvant Hemithoracic IMRT for MPM
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 08-0106-C, NCT00797719
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02015, CDR0000665415, S0905, U10CA032102, SWOG-S0905, NCT01064648
Axitinib in Malignant Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NL25655.031.08, NCT01211275
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110160, 11-C-0160, NCT01362790
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 66
Sponsor: NCI
Protocol IDs: 120111, 12-C-0111, NCT01583686
Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL/12/0158, CMS # 1995, A15183, 2012-001598-10, TBC, NCT01590160
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 21 and over
Sponsor: Other
Protocol IDs: OS-MES-P2-01, NCT01627795
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: INFLuenCe - Meso, NCT01644994
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1716-12, NCT01721018
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8962-002, NCT01898156
Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: ONC-2011-001, NCT02049060
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140053, 14-C-0053, NCT02054104
aDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 12-110, 5P01CA132714-05, NCT02151448
A Phase I/IIa Study of BMS-986148 in Subjects With Select Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA008-002, 2014-002485-70, NCT02341625
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: D8807005, NCT02347917
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2727.00, NCI-2015-00329, P30CA015704, NCT02408016
Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2 Therapy Following Cyclophosphamide and Fludarabine in Patients With Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: TILs-003-Meso, NCT02414945
A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GIMe/01/06, NCT00551252
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TL139204, NCT00685204
Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-053, NCT00715611
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: AAAB9658 (A6), NCT00859495
Start Over